Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice?
about
Prediction of the potency of mammalian cyclooxygenase inhibitors with ensemble proteochemometric modeling.Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer.Celecoxib sensitizes Staphylococcus aureus to antibiotics in macrophages by modulating SIRT1.Reactive aldehydes: a new player in inflammatory pain.Cardiomyocyte-specific Bmal1 deletion in mice triggers diastolic dysfunction, extracellular matrix response, and impaired resolution of inflammation.Obesity and Cardiometabolic Defects in Heart Failure Pathology.Diclofenac induces proteasome and mitochondrial dysfunction in murine cardiomyocytes and hearts.Comprehensive review of cardiovascular toxicity of drugs and related agents.Targeting ALDH2 for Therapeutic Interventions in Chronic Pain-Related Myocardial Ischemic Susceptibility.Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-γ-linolenic acid peroxidation dependent mechanism.Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practiceRisk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A multi-country European database study within the SOS ProjectCelecoxib in breast cancer prevention and therapy
P2860
Q27902278-2F11FCEA-62DC-4BD7-87CB-B5C703D38C9FQ33713908-2A38A840-92EF-4C6B-B944-92C1CB659B3EQ35192174-947B6B72-0015-4C8A-A865-0DB97D9D3B95Q40858853-DDDE3A26-7761-4A53-9CB5-42F087238FDBQ41369648-AF2EBFBA-A5EE-4331-A58E-75A2941BED48Q41997642-A5B5978D-652C-437F-8AAA-0DC5582A399CQ46055251-6CC6DBEC-5E23-4532-8A3F-8666B0EE45A4Q47556269-0EA7C3F5-DDE6-4474-9A95-8D92D6162F72Q49788134-7043B710-C737-4E5C-BCF7-EEAC2A0C1EF9Q52627350-249CAC26-B397-48A1-951C-1E04FB8DB52CQ57072074-8CF5159E-7EC8-4166-8488-306AF6B34B9CQ58720209-1289C69C-F7E5-44C5-A124-7B161D51FBDBQ59135502-4BA9673C-F462-49D3-A484-3029A00B515B
P2860
Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Selective COX-2 inhibitors, NS ...... s celecoxib the safest choice?
@ast
Selective COX-2 inhibitors, NS ...... s celecoxib the safest choice?
@en
type
label
Selective COX-2 inhibitors, NS ...... s celecoxib the safest choice?
@ast
Selective COX-2 inhibitors, NS ...... s celecoxib the safest choice?
@en
prefLabel
Selective COX-2 inhibitors, NS ...... s celecoxib the safest choice?
@ast
Selective COX-2 inhibitors, NS ...... s celecoxib the safest choice?
@en
P2860
P1476
Selective COX-2 inhibitors, NS ...... s celecoxib the safest choice?
@en
P2093
Laurence Guy Howes
P2860
P304
P577
2007-10-01T00:00:00Z